PL3110840T3 - A22k, desb27, b29r, des b30 w pozycji epsilon lizyny 22 zacylowany analog insuliny ludzkiej - Google Patents
A22k, desb27, b29r, des b30 w pozycji epsilon lizyny 22 zacylowany analog insuliny ludzkiejInfo
- Publication number
- PL3110840T3 PL3110840T3 PL15707102T PL15707102T PL3110840T3 PL 3110840 T3 PL3110840 T3 PL 3110840T3 PL 15707102 T PL15707102 T PL 15707102T PL 15707102 T PL15707102 T PL 15707102T PL 3110840 T3 PL3110840 T3 PL 3110840T3
- Authority
- PL
- Poland
- Prior art keywords
- desb27
- lysine
- des
- human insulin
- insulin analogue
- Prior art date
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title 1
- 239000004472 Lysine Substances 0.000 title 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 title 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14157215 | 2014-02-28 | ||
| PCT/EP2015/053989 WO2015128403A2 (en) | 2014-02-28 | 2015-02-26 | Novel insulin derivatives and the medical uses hereof |
| EP15707102.8A EP3110840B1 (en) | 2014-02-28 | 2015-02-26 | An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3110840T3 true PL3110840T3 (pl) | 2021-04-06 |
Family
ID=50184804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15707102T PL3110840T3 (pl) | 2014-02-28 | 2015-02-26 | A22k, desb27, b29r, des b30 w pozycji epsilon lizyny 22 zacylowany analog insuliny ludzkiej |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10040839B2 (enExample) |
| EP (1) | EP3110840B1 (enExample) |
| JP (1) | JP6580583B2 (enExample) |
| KR (1) | KR20160125988A (enExample) |
| CN (1) | CN106459171B (enExample) |
| AR (1) | AR099569A1 (enExample) |
| AU (1) | AU2015222135B2 (enExample) |
| BR (1) | BR112016017193A2 (enExample) |
| CA (1) | CA2941103A1 (enExample) |
| DK (1) | DK3110840T3 (enExample) |
| ES (1) | ES2831848T3 (enExample) |
| HR (1) | HRP20201732T1 (enExample) |
| HU (1) | HUE051355T2 (enExample) |
| IL (1) | IL246757B (enExample) |
| MX (1) | MX368387B (enExample) |
| PL (1) | PL3110840T3 (enExample) |
| PT (1) | PT3110840T (enExample) |
| RS (1) | RS61137B1 (enExample) |
| RU (1) | RU2684456C2 (enExample) |
| SA (1) | SA516371705B1 (enExample) |
| SI (1) | SI3110840T1 (enExample) |
| TW (1) | TWI686403B (enExample) |
| WO (1) | WO2015128403A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015131902A1 (en) * | 2014-03-07 | 2015-09-11 | Jørgensen Klavs Holger | Novel fast acting insulin preparations |
| CN108026157B (zh) | 2015-08-25 | 2022-11-25 | 诺和诺德股份有限公司 | 新型胰岛素衍生物及其医学用途 |
| WO2018094388A1 (en) * | 2016-11-21 | 2018-05-24 | Case Western Reserve University | Rapid-acting insulin analogues of enhanced stability |
| KR101909052B1 (ko) * | 2017-02-09 | 2018-10-17 | 강원대학교산학협력단 | 인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물 |
| EP3606560A2 (en) * | 2017-04-05 | 2020-02-12 | Novo Nordisk A/S | Oligomer extended insulin-fc conjugates |
| JOP20190273A1 (ar) * | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
| AU2018317810A1 (en) * | 2017-08-17 | 2020-03-19 | Novo Nordisk A/S | Novel acylated insulin analogues and uses thereof |
| MA50414A (fr) * | 2017-10-19 | 2020-08-26 | Mona E Buice | Composition à usage topique pour la cicatrisation améliorée des plaies ouvertes |
| TWI829687B (zh) * | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| SG11202106168VA (en) | 2018-12-11 | 2021-07-29 | Sanofi Sa | Insulin analogs having reduced insulin receptor binding affinity |
| CA3127312A1 (en) | 2019-02-13 | 2020-08-20 | Sumitomo Dainippon Pharma Co., Ltd. | Hemiasterlin derivative having cysteine residue |
| JP7479302B2 (ja) * | 2019-02-13 | 2024-05-08 | 住友ファーマ株式会社 | ヘミアスタリン誘導体とその抗体薬物複合体 |
| MX2022002433A (es) * | 2019-08-27 | 2022-05-19 | Zp Spv 3 K/S | Análogos de compstatina y sus usos médicos. |
| MA58093B1 (fr) | 2019-12-11 | 2024-09-30 | Novo Nordisk A/S | Nouveaux analogues d'insuline et leurs utilisations |
| WO2021136293A1 (zh) * | 2019-12-30 | 2021-07-08 | 甘李药业股份有限公司 | 胰岛素衍生物 |
| JP2024521757A (ja) * | 2021-05-24 | 2024-06-04 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 新規なアシル化インスリンアナログ |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3528960A (en) | 1968-10-07 | 1970-09-15 | Lilly Co Eli | N-carboxyaroyl insulins |
| US3869437A (en) | 1970-05-08 | 1975-03-04 | Nat Res Dev | Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin |
| GB1381274A (en) | 1971-01-28 | 1975-01-22 | Nat Res Dev | Insulin derivatives |
| US3864325A (en) | 1971-11-18 | 1975-02-04 | Nat Res Dev | (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives |
| JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
| JPH04502465A (ja) * | 1988-12-23 | 1992-05-07 | ノボ ノルディスク アクティーゼルスカブ | ヒトインシュリン類似物質 |
| EP0506792B1 (en) * | 1989-12-21 | 1995-05-17 | Novo Nordisk A/S | Insulin preparations containing nicotinic acid or nicotinamide |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| BR9407508A (pt) | 1993-09-17 | 1997-01-07 | Novo Nordisk As | Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento |
| US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| US6703017B1 (en) * | 1994-04-28 | 2004-03-09 | Ixion Biotechnology, Inc. | Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures |
| US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| US5646242A (en) | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
| US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| AU720966B2 (en) | 1995-03-17 | 2000-06-22 | Novo Nordisk A/S | Insulin derivatives |
| US6251856B1 (en) | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
| US6451970B1 (en) | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
| US5905140A (en) | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
| US5898067A (en) | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
| ATE321783T1 (de) | 1997-03-20 | 2006-04-15 | Novo Nordisk As | Zinkfreie insulinkristalle für die verwendung in medikamenten, die über die lunge verabreicht werden. |
| AU757933B2 (en) | 1997-10-24 | 2003-03-13 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
| US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| EA200000453A1 (ru) | 1997-10-24 | 2000-10-30 | Эли Лилли Энд Компани | Композиции нерастворимого инсулина |
| US6451762B1 (en) | 1997-10-24 | 2002-09-17 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| CO4970787A1 (es) | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
| WO1999034821A1 (en) | 1998-01-09 | 1999-07-15 | Novo Nordisk A/S | Stabilised insulin compositions |
| EP1086130A1 (en) | 1998-06-12 | 2001-03-28 | Kings College London | Insulin analogue |
| EP1196446A1 (en) | 1999-06-29 | 2002-04-17 | Eli Lilly And Company | Protamine-free insoluble acylated insulin compositions |
| AU2001264789A1 (en) | 2000-06-08 | 2001-12-17 | Eli Lilly And Company | Protein powder for pulmonary delivery |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| WO2003048195A2 (en) | 2001-12-02 | 2003-06-12 | Novo Nordisk A/S | Glucose dependant release of insulin from glucose sensing insulin derivatives |
| BR0215029A (pt) | 2001-12-20 | 2005-12-20 | Lilly Co Eli | Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus |
| WO2003075950A1 (en) | 2002-03-13 | 2003-09-18 | Novo Nordisk A/S | Minimising body weight gain in insulin treatment |
| US20040138099A1 (en) | 2002-11-29 | 2004-07-15 | Draeger Eberhard Kurt | Insulin administration regimens for the treatment of subjects with diabetes |
| WO2004096854A2 (en) | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
| US20060183667A1 (en) | 2003-07-11 | 2006-08-17 | Novo Nordisk A/S | Stabilised insulin compositions |
| EP1644411A2 (en) | 2003-07-11 | 2006-04-12 | Novo Nordisk A/S | Stabilised insulin compositions |
| CA2531988C (en) | 2003-08-05 | 2016-06-28 | Novo Nordisk A/S | Novel insulin derivatives |
| AU2004264958B2 (en) | 2003-08-13 | 2010-04-15 | Biocon, Ltd | Micro-particle fatty acid salt solid dosage formulations for therapeutic agents |
| JP2007532096A (ja) | 2003-11-14 | 2007-11-15 | ノボ ノルディスク アクティーゼルスカブ | アシル化されたインスリンの製造方法 |
| EP1692168B1 (en) | 2003-12-03 | 2011-07-20 | Novo Nordisk A/S | Single-chain insulin |
| WO2006008238A1 (en) | 2004-07-16 | 2006-01-26 | Novo Nordisk A/S | Method for selective acylation |
| RU2527893C2 (ru) | 2004-07-19 | 2014-09-10 | Биокон Лимитед | Инсулин-олигомерные конъюгаты, их препараты и применения |
| ES2438145T3 (es) | 2005-02-02 | 2014-01-16 | Novo Nordisk A/S | Nuevos derivados de insulina |
| ES2490243T3 (es) | 2005-02-02 | 2014-09-03 | Novo Nordisk A/S | Derivados de insulina |
| WO2006097521A1 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Pegylated single-chain insulin |
| JP4808785B2 (ja) | 2005-12-28 | 2011-11-02 | ノボ・ノルデイスク・エー／エス | インスリン組成物および組成物の製造方法 |
| JP5202338B2 (ja) | 2006-02-27 | 2013-06-05 | ノボ・ノルデイスク・エー／エス | 新規インシュリン誘導体 |
| EP2024390B1 (en) | 2006-05-09 | 2015-08-19 | Novo Nordisk A/S | Insulin derivative |
| AU2007247109B2 (en) | 2006-05-09 | 2012-03-15 | Novo Nordisk A/S | Insulin derivative |
| EP2076242B8 (en) | 2006-07-27 | 2013-02-20 | Nektar Therapeutics | Aerosolizable formulation comprising insulin for pulmonary delivery |
| JP5550338B2 (ja) | 2006-07-31 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | ペグ化持続型インスリン |
| US9018161B2 (en) * | 2006-09-22 | 2015-04-28 | Novo Nordisk A/S | Protease resistant insulin analogues |
| WO2008145721A2 (en) | 2007-06-01 | 2008-12-04 | Novo Nordisk A/S | N-terminal modification of polypeptides for protection against degradation by aminopeptidases |
| ES2744384T3 (es) | 2007-06-13 | 2020-02-24 | Novo Nordisk As | Formulación farmacéutica que comprende un derivado de insulina |
| WO2009015456A1 (en) | 2007-07-30 | 2009-02-05 | Generex Pharmaceuticals Inc. | Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray |
| AU2008288413B2 (en) | 2007-08-15 | 2013-09-26 | Novo Nordisk A/S | Insulin analogues with an acyl and aklylene glycol moiety |
| JP5715418B2 (ja) | 2007-11-08 | 2015-05-07 | ノボ・ノルデイスク・エー／エス | インスリン誘導体 |
| ES2430042T3 (es) | 2007-11-16 | 2013-11-18 | Novo Nordisk A/S | Composiciones farmacéuticas estables que comprenden liraglutida y degludec |
| MX338336B (es) | 2007-11-20 | 2016-04-07 | Ambrx Inc | Polipeptidos de insulina modificados y sus usos. |
| ES2618073T3 (es) * | 2008-03-14 | 2017-06-20 | Novo Nordisk A/S | Análogos de insulina estabilizados frente a proteasas |
| HUE032284T2 (en) | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
| WO2010029159A1 (en) | 2008-09-12 | 2010-03-18 | Novo Nordisk A/S | Method of acylating a peptide or protein |
| EP2352513B1 (en) | 2008-10-30 | 2016-09-14 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| CA2744558A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| EP2448962B1 (en) | 2009-06-30 | 2016-10-19 | Novo Nordisk A/S | Insulin derivatives |
| CA2769540C (en) * | 2009-07-31 | 2017-08-15 | Sanofi-Aventis Deutschland Gmbh | Long acting insulin composition |
| WO2011141407A1 (en) | 2010-05-10 | 2011-11-17 | Novo Nordisk A/S | Process for the preparation of insulin-zinc complexes |
| JP5973427B2 (ja) | 2010-06-23 | 2016-08-23 | ノヴォ ノルディスク アー／エス | 追加のジスルフィド結合を含有するインスリン類似体 |
| WO2011161125A1 (en) * | 2010-06-23 | 2011-12-29 | Novo Nordisk A/S | Insulin derivatives containing additional disulfide bonds |
| US9655974B2 (en) | 2010-07-20 | 2017-05-23 | Novo Nordisk A/S | N-terminal modified FGF21 compounds |
| US9260503B2 (en) | 2011-06-15 | 2016-02-16 | Novo Nordisk A/S | Multi-substituted insulins |
| AU2012328407A1 (en) | 2011-10-27 | 2014-05-22 | Case Western Reserve University | Ultra-concentrated rapid-acting insulin analogue formulations |
-
2015
- 2015-02-25 AR ARP150100559A patent/AR099569A1/es unknown
- 2015-02-26 TW TW104106145A patent/TWI686403B/zh not_active IP Right Cessation
- 2015-02-26 US US15/121,206 patent/US10040839B2/en active Active
- 2015-02-26 DK DK15707102.8T patent/DK3110840T3/da active
- 2015-02-26 PL PL15707102T patent/PL3110840T3/pl unknown
- 2015-02-26 CN CN201580010746.3A patent/CN106459171B/zh active Active
- 2015-02-26 RU RU2016135543A patent/RU2684456C2/ru active
- 2015-02-26 HR HRP20201732TT patent/HRP20201732T1/hr unknown
- 2015-02-26 EP EP15707102.8A patent/EP3110840B1/en active Active
- 2015-02-26 HU HUE15707102A patent/HUE051355T2/hu unknown
- 2015-02-26 SI SI201531416T patent/SI3110840T1/sl unknown
- 2015-02-26 BR BR112016017193A patent/BR112016017193A2/pt not_active Application Discontinuation
- 2015-02-26 JP JP2016554498A patent/JP6580583B2/ja active Active
- 2015-02-26 WO PCT/EP2015/053989 patent/WO2015128403A2/en not_active Ceased
- 2015-02-26 PT PT157071028T patent/PT3110840T/pt unknown
- 2015-02-26 MX MX2016010899A patent/MX368387B/es active IP Right Grant
- 2015-02-26 RS RS20201399A patent/RS61137B1/sr unknown
- 2015-02-26 ES ES15707102T patent/ES2831848T3/es active Active
- 2015-02-26 KR KR1020167024826A patent/KR20160125988A/ko not_active Withdrawn
- 2015-02-26 CA CA2941103A patent/CA2941103A1/en not_active Withdrawn
- 2015-02-26 AU AU2015222135A patent/AU2015222135B2/en not_active Ceased
-
2016
- 2016-07-13 IL IL246757A patent/IL246757B/en active IP Right Grant
- 2016-08-21 SA SA516371705A patent/SA516371705B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016010899A (es) | 2016-11-18 |
| CA2941103A1 (en) | 2015-09-03 |
| HRP20201732T1 (hr) | 2020-12-25 |
| WO2015128403A2 (en) | 2015-09-03 |
| US20170008945A1 (en) | 2017-01-12 |
| RU2016135543A3 (enExample) | 2018-08-30 |
| TWI686403B (zh) | 2020-03-01 |
| AU2015222135A1 (en) | 2016-07-28 |
| TW201620930A (zh) | 2016-06-16 |
| KR20160125988A (ko) | 2016-11-01 |
| SI3110840T1 (sl) | 2020-12-31 |
| IL246757A0 (en) | 2016-08-31 |
| WO2015128403A3 (en) | 2015-12-10 |
| JP6580583B2 (ja) | 2019-09-25 |
| US10040839B2 (en) | 2018-08-07 |
| AU2015222135B2 (en) | 2018-12-20 |
| RU2016135543A (ru) | 2018-03-30 |
| BR112016017193A2 (pt) | 2017-10-03 |
| EP3110840B1 (en) | 2020-10-21 |
| CN106459171B (zh) | 2020-12-15 |
| HUE051355T2 (hu) | 2021-03-01 |
| JP2017508741A (ja) | 2017-03-30 |
| RS61137B1 (sr) | 2020-12-31 |
| EP3110840A2 (en) | 2017-01-04 |
| RU2684456C2 (ru) | 2019-04-09 |
| AR099569A1 (es) | 2016-08-03 |
| SA516371705B1 (ar) | 2019-10-08 |
| ES2831848T3 (es) | 2021-06-09 |
| PT3110840T (pt) | 2020-11-26 |
| DK3110840T3 (da) | 2020-11-02 |
| MX368387B (es) | 2019-10-01 |
| IL246757B (en) | 2020-04-30 |
| CN106459171A (zh) | 2017-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE051355T2 (hu) | Epszilon-helyzetben A22K, DEZB27, B29R, DEZ B30 derivatizált lizin-22-acilezett humán inzulin analóg | |
| EP3236842A4 (en) | Patient worn sensor assembly | |
| ZA201802017B (en) | Novel insulin analogs and use thereof | |
| ZA201703507B (en) | Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof | |
| IL248668B (en) | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes | |
| IL249502A0 (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases | |
| GB201612165D0 (en) | Combinations for the treatment of type 2 diabetes | |
| PL3268029T3 (pl) | Leczenie pacjentów z cukrzycą typu 2 | |
| EP3171840A4 (en) | Improved medical implant | |
| EP3137063A4 (en) | Treatment of crohn's disease with delayed-release 6-mercaptopurine | |
| IL254500A0 (en) | Treatment of patients with type 2 diabetes | |
| EP3148556A4 (en) | Skin treatment formulations | |
| GB201707207D0 (en) | Treatment of type 1 diabetes | |
| IL248670A0 (en) | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes | |
| GB201403996D0 (en) | Traditional chinese medicine composition for the treatment of diabetes | |
| IL250594B (en) | The composition for the treatment of nerve diseases and/or neuropathic pain | |
| ZA201804588B (en) | Pharmaceutical formulations for the treatment of diabetes | |
| IL252543B (en) | Compounds for the treatment of degenerative retinal tissues | |
| EP3184055A4 (en) | Medical treatment instrument | |
| GB201401706D0 (en) | Nanoparticle-insulin and insulin analogue compositions | |
| DK3148588T3 (en) | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease | |
| HK1244688A1 (en) | Treatment of type 2 diabetes mellitus patients | |
| HK1230506A1 (en) | Treatment of crohn's disease with delayed-release 6-mercaptopurine | |
| IL237151A0 (en) | An innovative dental analog implant | |
| AU2015904246A0 (en) | Treatment of diabetes |